AtriCure gets 510(k) clearance for AtriClip device

Shares of West Chester, OH-based AtriCure soared on news that the FDA approved the company's AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion System, a device which blocks blood clots during heart procedures. AtriClip could bring in up to $300 million a year for the company. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.